Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibacterial agents: combination of a rifamycin and a switch region inhibitor

a switch region inhibitor and antibacterial agent technology, applied in the field of combination of rifamycin and switch region inhibitors, can solve the problems of grave and growing threat to public health infection, limited clinical utility of rifamycin, so as to reduce the minimum effective dose and reduce the frequency of spontaneous resistan

Active Publication Date: 2017-12-12
RUTGERS THE STATE UNIV
View PDF25 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes the discovery that combining a rifamycin and a switch-region inhibitor can create stronger antibacterial activity, even at low doses. This combination also results in a low resistance to treatment, which means it can be used to treat high-titer infections without failing due to resistance. Furthermore, using this combination can reduce the minimum effective dose and spontaneous resistance frequency of the rifamycin and the switch region inhibitor.

Problems solved by technology

Drug-resistant bacteria now cause infections that pose a grave and growing threat to public health.
However, the clinical utility of rifamycins is limited by hepatotoxicity that prevents administration of rifamycins at the concentrations that yield highest bacteriocidal kinetics.
The clinical utility also is limited by a relatively high frequency of spontaneous resistance (spontaneous resistance frequency of ˜6×10−8).
Compounds that bind to the switch region can interfere with opening or closing of the RNAP active-center cleft and can inhibit RNAP allosterically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial agents: combination of a rifamycin and a switch region inhibitor
  • Antibacterial agents: combination of a rifamycin and a switch region inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Co-Administration of Rifampin and the Switch-Region Inhibitor Myxopyronin B Results in Synergistic Antibacterial Activity

[0117]Compound-compound interactions were assessed in “checkerboard”-format broth-microdilution antibacterial susceptibility assays essentially as described [Berenbaum, M. (1978) A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122-130; Norden, C., Wentzel, H. & Keleti, E. (1979) Comparison of techniques for measurement of in vitro antibiotic synergism. J. Infect. Dis. 140, 629-633]. Assays were performed using Staphylococcus aureus ATCC 12600 (5×105 cfu / well) as the assay organism and Mueller-Hinton Broth II, Cation Adjusted (100 μl / well), as the assay medium, and 14 h at 37° C. as the assay incubation time.

[0118]Isobolograms were plotted and interpreted as described [Berenbaum, M. (1978) A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122-130; Norden, C., Wentzel, H. & Keleti, E. (1979) Comparison ...

example 2

Co-Administration of Rifampin and the Switch-Region Inhibitor Myxopyronin B Reduces Spontaneous Resistance to Undetectable Levels

[0121]Spontaneous resistance frequencies in Staphylococcus aureus were determined by plating defined numbers of cells of Staphylococcus aureus ATCC12600 (1×108-1×1012 cfu / plate) on Mueller-Hinton agar containing rifampin, myxopyronin B, or both, and counting numbers of colonies after 14 h at 37° C. Experiments were performed using (a) rifampin at 1×, 2×, or 4× the minimum inhibitory concentration of rifampin administered individually; (b) myxopyronin B at lx, 2×, or 4× the minimum inhibitory concentration of myxopyronin B administered individually; or (c) both rifampin at 1×, 2×, or 4× the minimum inhibitory concentration of rifampin administered individually and myxopyronin B at 1×, 2×, or 4× the minimum inhibitory concentration of myxopyronin B administered individually. All experiments were performed four times, using four different starting cultures.

[0...

example 3

Co-Administration of Rifampin and the Switch-region Inhibitor Lipiarmycin A3 Results in Synergistic Antibacterial Activity

[0129]Compound-compound interactions were assessed as in Example 1. The isobologram is presented in FIG. 2. All isobologram points for the co-administration of rifampin and lipiarmycin A3 were located below the diagonal, indicating that the co-administration of rifampin and lipiarmycin A3 resulted in super-additive, synergistic antibacterial activity. Co-administration resulted in a 12-fold reduction in the minimal inhibitory concentration of rifampin and 2-fold reduction in the minimal inhibitory concentration of lipiarmycin A3 (second point from left), a 4-fold reduction in the minimal inhibitory concentration of rifampin and 2.7-fold reduction in the minimal inhibitory concentration of lipiarmycin A3 (third point from left), or a 2-fold reduction in the minimal inhibitory concentration of rifampin and 4-fold reduction in the minimal inhibitory concentration of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
resistanceaaaaaaaaaa
concentrationsaaaaaaaaaa
frequencyaaaaaaaaaa
Login to View More

Abstract

It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and / or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide a composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATION(S)[0001]This patent application claims the benefit of priority of U.S. Application Ser. No. 61 / 595,488, filed Feb. 6, 2012, which application is herein incorporated by reference.GOVERNMENT FUNDING[0002]The invention described herein was made with government support under Grant Numbers AI072766 and AI090837 awarded by the National Institutes of Health. The United States Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Bacterial infections remain among the most common and deadly causes of human disease. Infectious diseases are the third leading cause of death in the United States and the leading cause of death worldwide (Binder et al. (1999) Science 284, 1311-1313). Drug-resistant bacteria now cause infections that pose a grave and growing threat to public health. It has been shown that bacterial pathogens can acquire resistance to first-line and even second-line antibiotics (Walsh, C. (2000) Nature 406, 775-781; Sc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/496A61K31/366A61K31/395A61K31/70A61K31/7048
CPCA61K31/496A61K31/366A61K31/395A61K31/70A61K31/7048A61K2300/00Y02A50/30
Inventor EBRIGHT, RICHARD H.
Owner RUTGERS THE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com